Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for patients with small liver tumors, specifically those that are 4 cm or less in size. The goal is to see how effective a technique called microwave ablation is at safely destroying these tumors while also ensuring that a healthy margin of tissue around the tumor is preserved. Researchers will track how well the treatment works by checking if the tumors come back within a year after the procedure using imaging tests.

To participate in this trial, patients should have certain types of liver cancer and meet specific health criteria, such as having mild to moderate liver function (Child-Pugh Class A or B). However, individuals with multiple tumors, larger tumors, or severe liver issues may not be eligible. If you qualify, you can expect to undergo a procedure using a specialized microwave device to treat your liver cancer, and your progress will be monitored through follow-up imaging. This study is still recruiting participants, and it aims to provide valuable information about a promising treatment for liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Child-Pugh Class A or B
• • Patients with suspected hepatocellular carcinoma or residual/recurrent hepatocellular carcinoma of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days or Patients with suspected metastatic liver cancer of 4 cm or less on MDCT, CEUS, or MRI performed within the last 60 days, for whom microwave thermal ablation is being considered
• Exclusion Criteria:
• • In cases where there are three or more malignant liver tumors
• • When the maximum size of the tumor exceeds 4 cm
• • Diffuse infiltrative type of cancer with unclear tumor boundaries
• • When the tumor is adhered to the central hepatic portal vein, hepatic vein, or bile duct by 5 mm or more
• • Severe liver failure (Child-Pugh Class C)
• • In cases of vascular invasion by malignant liver tumors
• • Severe coagulopathy (platelet count below 50,000/mm³ or INR prolonged by more than 50%)
• • In cases of multiple extrahepatic metastases
• • Situations where it is highly unlikely to obtain appropriate data for research purposes